BioPharma Clinical Trials

Enveda Biosciences Secures $55 Million in Latest Financing Round

Enveda Biosciences a biotechnology company using AI to translate nature into new medicines, announced today a new financing round of $55 million to add to ...

 June 17, 2024 | News

SciRhom GmbH Secures Approval for Clinical Trial Application of SR-878 in Austria

SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced the approval of a clinical trial a...

 June 14, 2024 | News

IQVIA Launches One Home for Sites™ to Streamline Clinical Trial Management

IQVIA announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems...

 June 13, 2024 | News

GC Biopharma and Novel Pharma Receive FDA Fast Track Designation for Sanfilippo Syndrome Treatment GC1130A

GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA (Sanfili...

 June 11, 2024 | News

DeepQure Initiates Early Feasibility Study for Groundbreaking HyperQure™ System Following FDA Approval

DeepQure, a Seoul based medical device company with a novel, extravascular (laparoscopic approach) solution for renal denervation (RDN), announce...

 June 11, 2024 | News

Vertex's TRIKAFTA® Shows Significant Clinical Benefits in Cystic Fibrosis Patients with Rare Mutations

Results from a randomized, placebo-controlled study of TRIKAFTA® in people with cystic fibrosis with rare, non-F508del CFTR mutations s...

 June 10, 2024 | News

MLB Receives FDA Approval for TML-6 IND Application to Treat Alzheimer's Disease

MLB (Merry Life Biomedical Company, Ltd., Taiwan )  a biomedical company, announced that  the U.S. Food and Drug Administration (FDA) h...

 June 07, 2024 | News

Shanghai MicuRx Achieves Key Milestone in Combatting Drug-Resistant Infections with Successful Phase I Trial of MRX-8

According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant b...

 June 07, 2024 | News

I-Mab Partners with Bristol Myers Squibb for Phase 1 Clinical Trial of Novel Cancer Therapy

I-Mab , a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapi...

 June 06, 2024 | News

Thermo Fisher Scientific Opens Cutting-Edge Ultra-Cold Facility in EU to Boost Advanced Therapy Development

Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new clinical and commercial ultra-cold facility in the EU, expanding its c...

 June 03, 2024 | News

AstraZeneca’s TAGRISSO® Shows Significant Improvement in Progression-Free Survival in Phase III LAURA Trial for EGFR-Mutated NSCLC

Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant a...

 June 03, 2024 | News

EMA CHMP Recommends Approval of Sugemalimab for First-Line Treatment of NSCLC

EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and ...

 June 03, 2024 | News

Fortrea Launches Comprehensive Solution to Enhance Diversity and Inclusion in Clinical Trials

 Fortrea, a leading global contract research organization (CRO), today announced its comprehensive and integrated solution to improve the diversity an...

 May 31, 2024 | News

Kexing Biopharm’s Subsidiary Receives Approval for Clinical Trials of Innovative GB08 Growth Hormone

Kexing Biopharm announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently received a Notice of Approval for Drug Clini...

 May 31, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close